Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.

Urs B HagemannChristine EllingsenJoachim SchuhmacherAlexander KristianAnne MobergslienVéronique CrucianiKatrine WickstroemChristoph A SchatzChristoph KneipSven GolfierRoger SmeetsSteinar UranHartwig HennekesJenny KarlssonRoger M BjerkeOlav B RyanDominik MumbergKarl ZiegelbauerAlan S Cuthbertson

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

These promising preclinical results supported the transition of BAY 2287411 into a clinical phase I program in mesothelioma and ovarian cancer patients (NCT03507452).

Keyphrases

cancer therapy
cell therapy
drug delivery
stem cells
young adults
childhood cancer